China SXT Pharmaceuticals
SXTC
0 hedge funds and large institutions have $6 invested in China SXT Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
9.16% less ownership
Funds ownership: 9.16% → 0% (-9.2%)
100% less funds holding
Funds holding: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $131K → $6 (-$131K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$131K |
SXTC Hedge Fund Activity: Q2 2026 in Review
0 of the 8,343 institutional investors tracked by Wall St. Rank reported a position in China SXT Pharmaceuticals (SXTC) for Q2 2026, worth a combined $6 — down 100% from $131K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of SXTC and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Sabby Management, exiting entirely with an estimated $131K sold.
- 0 institutional investors held China SXT Pharmaceuticals (SXTC) as of Q2 2026, down from 1 in Q1 2026.
- Funds reported $6 of China SXT Pharmaceuticals stock for Q2 2026, down 100% quarter-over-quarter.
- 0 funds opened new China SXT Pharmaceuticals positions in Q2 2026 and 1 closed out, a net change of -1 holder.
- The largest China SXT Pharmaceuticals seller in Q2 2026 was Sabby Management, an estimated $131K sold.
Based on aggregated 13F filings for Q2 2026.